Taiwan Liposome Co (台灣微脂體) is expected to raise NT$591.36 million (US$20.31 million) from its initial public offering (IPO) on Friday next week, with the firm planning to use the proceeds to improve its gross margin and strengthen its bottom line.
The biopharmaceutical company, headquartered in Taipei’s Nangang Software Park (南港軟體園區), plans to issue 4.62 million new shares on its the GRETAI Securities Market debut and has tentatively set the IPO price at NT$128, the company said.
On Monday, Taiwan Liposome began book building for institutional investors after receiving regulatory approval. The book building, whereby institutional investors make bids for the stock on offer, ends on Thurday, the company said.
Taiwan Liposome currently trades on the smaller Emerging Stock Market, a preparatory board for the nation’s two main bourses. Its shares closed 1.64 percent higher yesterday at NT$279.50, rising 288.9 percent so far this year, according to stock exchange data.
The company reported a net income of NT$24.3 million, or earnings per share of NT$0.62, in the third quarter, after posting a net loss of NT$40.69 million, or a net loss per share of NT$1.04 per share, in the first half of the year.
In the first three quarters of the year, Taiwan Liposome posted a net loss of NT$16.34 million, or loss per share of NT$0.42, much lower than a net loss of NT$137.43 million, or NT$5.11 per share, a year earlier, company data showed.
During the first 11 months of the year, sales surged 210.7 percent to NT$233.195 million from NT$75.048 million a year ago, the company said on Monday.
Analysts say the company is likely to swing into profit next year on the back of certain milestone payments and royalties on product sales. Taiwan Liposome reported a net loss of NT$216.99 million last year, NT$190.21 million in 2010 and NT$184.07 million in 2009.
Established in 1997, Taiwan Liposome focuses on the research and development of pharmaceutical products based on its proprietary drug delivery technologies.
“Traditionally, drugs are transmitted via blood, and the amount of drugs that can reach infected organs is little,” Taiwan Liposome president George Yeh (葉志鴻) said at a pre-IPO conference for investors on Nov. 28.
“We use lipid-based formulation that delivers the drug to infected body parts and releases the drug there, creating better efficacy and lower toxicity for the drugs,” Yeh said.
Lipid-based formulations can also be used to control the amount of drugs released in a given period of time, prolonging the product lifecycle of drugs.
In the past few years, Taiwan Liposome has developed drugs used to treat breast cancer and ovarian cancer, such as Lipo-Dox and Doxisome, as well as ProFlow, a drug used to treat peripheral vascular disease. The company is expected to invest NT$1.15 billion into new drug development from this year through 2016.
The Financial Supervisory Commission (FSC) yesterday fined Citibank Taiwan Ltd (花旗台灣) NT$10 million (US$357,194) and DBS Bank Taiwan (星展台灣) NT$6 million for breaches of the nation’s anti-money laundering (AML) regulations. The NT$10 million fine is the highest penalty that it has imposed on a domestic bank, the commission said. Citibank Taiwan failed to set up a sound mechanism for evaluating clients’ risk of money laundering and for detecting suspicious transactions, Banking Bureau Deputy Director-General Huang Kuang-hsi (黃光熙) told a news conference in New Taipei City. The bank based its AML policies on those of its US-based parent company, Citigroup Inc, but the policies
The rise of the cryptocurrency dogecoin has reached a new level after the token was used to pay for a lunar satellite launch. SpaceX, Elon Musk’s commercial rocket firm, is to embark on a moon voyage next year carrying a so-called cubesat — a mini-satellite used for space research — from Geometric Energy Corp that has been paid for entirely in dogecoin. The development is the latest twist in the saga over the digital token, which started as a joke in 2013, but is now a dominating Internet meme and sitting on a 21,000 percent rally in the past year. Musk has
CAPACITY EXPANSION: Construction of the site, which is to be the firm’s first mRNA production facility outside of Europe, is to begin this year and likely finish in 2023 COVID-19 vaccine maker BioNTech SE yesterday said it would build a Southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of messenger RNA (mRNA)-based vaccines per year. Construction of the site would start this year, and it could become operational by 2023, the German company said in a statement. “With this planned mRNA production facility, we will increase our overall network capacity, and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” BioNTech chief executive Ugur Sahin said. The vaccine produced by BioNTech jointly with Pfizer Inc of
COMPETITIVE: The chip designer is offering an annual compensation of NT$1.5 million to NT$2 million, in addition to cash and stock bonuses to attract workers MediaTek Inc (聯發科), the world’s biggest designer of 5G handset chips, is stepping up its recruitment drive this year, with plans to hire more than 2,000 engineers specializing in core technologies, including 5G, wireless communication and artificial intelligence (AI). That would be double from the more than 1,000 people it hired on average in the past few years, as the Hsinchu-based company looks to boost growth this year and beyond. It also comes as the company plans to launch a new 5G chip, Dimensity 2000 series, which supports mmWave technology and sub-6-gigahertz technology, at the end of this year. That would be